FDA Limits Use Of Stryker's Wingspan Anti-Stroke Stent
The U.S. Food and Drug Administration on Wednesday significantly narrowed the group of patients allowed to use Stryker Corp.'s Wingspan brain artery-opening stent, after recent trials showed an increased risk of...To view the full article, register now.
Already a subscriber? Click here to view full article